reglab/housing_qa huggingface dataset:
CA Health & Safety Code § 111470 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111470.

111470.  The following drugs or devices, that are intended for use by man, shall be sold only upon a written prescription of a practitioner licensed by law to prescribe the drug or device, or upon an oral prescription of the licensee that is reduced promptly to writing and filed by the pharmacist, or by refilling the written or oral prescription if the refilling is authorized by the prescriber either in the original prescription or by oral order that is reduced promptly to writing and filed by the pharmacist:(a)  A habit forming drug to which Section 111350 applies. (b)  A drug or device that, because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer the drug or device. (c)  A drug or device for which adequate directions cannot be written for persons, who are not practitioners licensed by law to prescribe the drug or device, for safe and effective self-medication or treatment by those persons, who are not practitioners licensed by law to prescribe the drug or device. (d)  A drug or device that is limited by an effective application under Section 505 of the federal act (21 U.S.C. Sec. 355) or Section 111550 to use under the professional supervision of a practitioner licensed by law to administer the drug or device. If any prescription for the drug does not indicate the number of times it may be refilled, if any, the prescription may not be refilled unless the pharmacist obtains a new order from the practitioner.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111475 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111475.

111475.  The act of selling a drug or device contrary to Section 111470 shall be deemed to be an act that results in the drug or device being misbranded while held for sale.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111480 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111480.

111480.  Any drug or device sold by filling or refilling a written or oral prescription of a practitioner licensed to prescribe the drug or device shall be exempt from the labeling requirements of Sections 111335, 111340, 111350, 111355, 111360, 111365, 111375, 111380, 111385, 111395, 111415, and 111420, if the drug or device bears a label displaying all the following:(a)  Except where the prescriber orders otherwise, either the manufacturer’s trade name of the drug, or the generic name and the name of the manufacturer. Commonly used abbreviations may be used. Preparations containing two or more active ingredients may be identified by the manufacturer’s trade name or the commonly used name or the principal active ingredients. (b)  The directions for the use of the drug or device. (c)  The name of the patient(s). (d)  The name of the prescriber. (e)  The date of issue. (f)  The name, address of the furnisher, and prescription number or other means of identifying the prescription. (g)  The strength of the drug or drugs dispensed. (h)  The quantity of the drug or drugs dispensed. (i)  The expiration date of the effectiveness of the drug or device if the information is included on the original label of the manufacturer of the drug or device. If a pharmacist dispenses a prescribed drug by means of a unit dose medication system, as defined by administrative regulation, for a patient in a skilled nursing, intermediate care or other health care facility, the requirements of this section will be satisfied if the unit dose medication system contains the aforementioned information or the information is otherwise readily available at the time of drug administration.The exemption shall not apply to any drug or device dispensed in the course of the conduct of a business of dispensing drugs or devices pursuant to diagnosis by mail, or to a drug or device dispensed in violation of Section 111470.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111485 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111485.

111485.  The department may, by regulation, remove any drug or device subject to Sections 111350 and 111550 from the requirements of Section 111470, when the requirements are not necessary for the protection of the public health. Any drug removed from the prescription requirements of the federal act by regulations adopted pursuant to the federal act is removed from the requirements of Section 111470. The department may, however, by regulation, continue the applicability of Section 111470 for any drug or device, or make these sections inapplicable to any drug or device, whether or not the inclusion or exclusion of the drug or device is in accordance with the regulations adopted pursuant to the federal act.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111490 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111490.

111490.  (a)  A drug or device that is subject to Section 111470 is misbranded if at any time prior to dispensing, its label fails to bear the statement “Caution: federal law prohibits dispensing without prescription,” or “Caution: state law prohibits dispensing without prescription,” or “R x only.” A drug or device to which Section 111470 does not apply is misbranded if at any time prior to dispensing its label bears the caution statement or “R x only” quoted in the preceding sentence. (b)  A device that is subject to Section 111470 is misbranded if, at any time prior to dispensing, its label fails to bear the statement “Caution: federal law restricts this device to sale by or on the order of a ____ ,” the blank to be filled in with the designation of the practitioner licensed to use or order use of the device. A device to which Section 111470 does not apply is misbranded if, at any time prior to dispensing, its label bears the caution statement quoted in the preceding sentence. (Amended by Stats. 2000, Ch. 796, Sec. 12. Effective January 1, 2001.)
CA Health & Safety Code § 111495 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111495.

111495.  Nothing in this article shall be construed to relieve any person from any requirement prescribed by or under authority of law with respect to drugs now included or that may hereafter be included within the classification stated in Division 10 (commencing with Section 11000) or in the applicable federal law relating to controlled substances.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111500 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111500.

111500.  A physician, dentist, podiatrist, or veterinarian may personally furnish his or her own patient with drugs as are necessary in the treatment of the condition for which he or she attends the patient provided that the drug is properly labeled to show all the information required in Section 111480 except the prescription number.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111505 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111505.

111505.  For purposes of Section 111510, the following definitions shall apply:(a)  “Distributor” means any corporation, person, or other entity, not engaged in the manufacture of a legend drug product, who distributes for resale and distribution a legend drug product under the label of the corporation, person, or entity. (b)  “Legend drug” means any controlled substance subject to the Federal Controlled Substances Act (Title II, P.L. 91-513) or subject to the Uniform Controlled Substances Act, Division 10 (commencing with Section 11000), and any drug described in Section 4211 of the Business and Professions Code or Section 111470. (c)  “Solid dosage forms” means capsules or tablets intended for oral administration. (d)  “Code imprint” means a series of letters or numbers assigned by the manufacturer or distributor to a specific drug, or marks or monograms unique to the manufacturer, distributor, or both. The National Drug Code may be used as a code imprint. (Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111510 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 3 - Misbranded Drugs or Devices|Section 111510.

111510.  (a)  No legend drug in solid dosage form may be manufactured or distributed for sale in this state unless it is clearly marked or imprinted with a code imprint identifying the drug and the manufacturer or distributor of the drug. Manufacturers or distributors who only repack an already finished dosage form of a legend drug shall not have the responsibility to do the imprint. (b)  On or before July 1, 1982, manufacturers or distributors of legend drugs, depending on whether the manufacturer’s or distributor’s code imprint will appear on the surface of the solid dosage form, shall provide to the department a list of their legend drugs and the intended code imprints. The department shall provide for the distribution of the information required to be submitted under this subdivision to all poison control centers in the state. Manufacturers, distributors, and the department shall provide to any licensed health care provider, upon request, lists of legend drugs and code imprints provided to the department under this section, but may charge a reasonable fee to cover copying and postage costs. Updated lists shall be provided to the department annually or as changes or revisions occur. (c)  The department may grant exemptions from the requirements of this section upon application of a manufacturer or distributor indicating size or other characteristics that render the product impractical for the imprinting required by this section. (d)  A legend drug that does not meet the requirements is misbranded. (e)  It is the intent of the Legislature that all legend drugs having solid dosage forms be imprinted regardless of by whom they are distributed. (f)  This section shall apply to all legend drugs sold in California on or after January 1, 1983. (g)  Pharmacists, pharmacies, and licensed wholesalers shall only be liable for knowing and willful violations of this section, except that no liability shall accrue if the pharmacist acts pursuant to Section 4229.5 of the Business and Professions Code. (h)  The provisions of subdivisions (a) to (g), inclusive, shall not apply to any of the following: (1)  Drugs purchased by a pharmacy, pharmacist, or licensed wholesaler prior to January 1, 1983, and held in stock for resale. (2)  Drugs that are the subject of an investigation pursuant to Section 111590 or 111595. (3)  Drugs that are manufactured by or upon the order of a practitioner licensed by law to prescribe or administer drugs and that are to be used solely by the patient for whom prescribed. (Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111515 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4 - Experimental Use of Drugs|Section 111515.

111515.  As used in this article, “experimental drug” means any of the following:A drug intended for investigational use under Section 111595.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111520 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4 - Experimental Use of Drugs|Section 111520.

111520.  No person shall prescribe or knowingly administer an experimental drug to another person in violation of this article.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111525 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4 - Experimental Use of Drugs|Section 111525.

111525.  Prior to prescribing or administering an experimental drug, consent to the use of the drug shall be obtained in the method and manner specified in Chapter 1.3 (commencing with Section 24170) of Division 20.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111530 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4 - Experimental Use of Drugs|Section 111530.

111530.  (a)  Notwithstanding the provisions of Section 24175, if the subject is a minor, consent shall be provided by a parent or guardian of the subject and shall also be provided by the subject if the subject is seven years of age or older. (b)  Consent given pursuant to this section shall only be for the prescribing or administering of an experimental drug that is related to maintaining or improving the health of the subject or related to obtaining information about a pathological condition of the subject. (Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111535 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4 - Experimental Use of Drugs|Section 111535.

111535.  Consent given pursuant to Section 111525 may be revoked at any time by either verbal or written communication to the practitioner supervising the administration of the experimental drug.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111540 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4 - Experimental Use of Drugs|Section 111540.

111540.  Prior to administering an experimental drug, the experimental activity as a whole, including the consent procedures required by Section 111525, shall be reviewed and approved by a committee for the protection of human subjects that is acceptable, as determined by the department. A committee for the protection of human subjects that operates under a general or special assurance approved by the federal Department of Health, Education, and Welfare pursuant to Part 46 of Title 45 of the Code of Federal Regulations shall be an acceptable committee for purposes of this section. A copy of the consent procedures approved by a committee for the protection of human subjects shall be filed with the department prior to the commencement of the experiment.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111545 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4 - Experimental Use of Drugs|Section 111545.

111545.  A person having an ownership interest in a skilled nursing facility or intermediate care facility, as those terms are defined in Section 1250, may not prescribe an experimental drug for a patient in the facility.(Added by Stats. 1995, Ch. 415, Sec. 6. Effective January 1, 1996.)
CA Health & Safety Code § 111548 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4.5 - Right to Try Act|Section 111548.

111548.  This article shall be known and may be cited as the Right to Try Act.(Added by Stats. 2016, Ch. 684, Sec. 1. (AB 1668) Effective January 1, 2017.)
CA Health & Safety Code § 111548.2 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4.5 - Right to Try Act|Section 111548.2.

111548.2.  (a) Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturer’s investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.(b) A manufacturer may do both of the following:(1) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.(2) Require an eligible patient to pay the costs of, or associated with, the manufacture of the investigational drug, biological product, or device.(c) (1) This article does not expand the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.(2) This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.(d) If the clinical trial for an investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity, the investigational drug, biological product, or device shall not be offered. If notice of closure of a clinical trial is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patient’s primary physician shall notify the patient of the information from the safety committee of the clinical trial. (e) If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patient’s heirs and health benefit plan, except to the extent the plan provided coverage pursuant to paragraph (2) of subdivision (c), are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.(Added by Stats. 2016, Ch. 684, Sec. 1. (AB 1668) Effective January 1, 2017.)
CA Health & Safety Code § 111548.3 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4.5 - Right to Try Act|Section 111548.3.

111548.3.  (a) Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physician’s license based on the physician’s recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physician’s institutional review board or an accredited independent institutional review board.(b) The physician’s institutional review board or an accredited institutional review board shall biannually report the following information to the State Department of Public Health, the Medical Board of California, and the Osteopathic Medical Board of California:(1) The number of requests made for an investigational drug, biological product, or device.(2) The status of the requests made.(3) The duration of the treatment.(4) The costs of the treatment paid by eligible patients. (5) The success or failure of the investigational drug, biological product, or device in treating the immediately life-threatening disease or condition from which the patient suffers.(6) Any adverse event for each investigational drug, biological product, or device.(c) A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care provider’s certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.(d) A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).(Added by Stats. 2016, Ch. 684, Sec. 1. (AB 1668) Effective January 1, 2017.)
CA Health & Safety Code § 111548.5 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 104 - ENVIRONMENTAL HEALTH|PART 5 - SHERMAN FOOD, DRUG, AND COSMETIC LAWS|CHAPTER 6 - Drugs and Devices|ARTICLE 4.5 - Right to Try Act|Section 111548.5.

111548.5.  This article does not create a private cause of action, and actions taken pursuant to this article shall not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.(Added by Stats. 2016, Ch. 684, Sec. 1. (AB 1668) Effective January 1, 2017.)